Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
TERMINATED
NCT00126230
PHASE2
Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
View on ClinicalTrials.gov
Summary
This is a prospective phase II trial of docetaxel-samarium in patients with hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine.
Official title: A Prospective Phase II Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer Who Achieve a Response or a Stabilization to Docetaxel-estramustine
Key Details
Gender
MALE
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
55
Start Date
2004-01
Completion Date
Not specified
Last Updated
2026-08-19
Healthy Volunteers
No
Conditions
Interventions
DRUG
docetaxel and samarium
Locations (1)
Institut Gustave Roussy
Villejuif, France